Facebook Pixel Vax Cocktail Endgame Against Covid-19 | BioSpectrum Asia – Business – Lesen Sie diese Geschichte auf Magzter.com
Mit Magzter GOLD unbegrenztes Potenzial nutzen

Mit Magzter GOLD unbegrenztes Potenzial nutzen

Erhalten Sie unbegrenzten Zugriff auf über 9.000 Zeitschriften, Zeitungen und Premium-Artikel für nur

$149.99
 
$74.99/Jahr

Versuchen GOLD - Frei

Vax Cocktail Endgame Against Covid-19

BioSpectrum Asia

|

BioSpectrum Asia Sep 2021

The world has been under the deadly spell of the coronavirus, with multiple waves of the pandemic decimating lives and economy in a fell swoop. In a record short span of time, numerous vaccines were developed to combat COVID-19. However, the ground reality seems, as per some experts, that administering a mix of vaccines presents better outcomes. Whether this approach holds good, needs a closer look.

- Ayesha Siddiqui

Vax Cocktail Endgame Against Covid-19

Vaccine mixing, which began unintentionally, is now gaining traction. There is a significant interest in mixing two different types of COVID-19 vaccines to mitigate against supply shocks or shortages that might otherwise reduce the speed of vaccine roll-out.

Canada which sort of started this trend unintentionally to manage its vaccine supply issues by allowing the mixing of vaccines. On June 1, 2021, the Canadian health agency, Health Canada asked those who had taken the Pfizer shot to take Moderna’s mRNA vaccine for their second dose. This has helped Canada overcome a supply bottleneck that delayed Pfizer doses in June.

Taking it even further, on June 17, 2021, the Canadian government recommended those who received the AstraZeneca (adenoviral vector-based vaccine) as the first dose should preferably take either the Pfizer or Moderna mRNA vaccine for their second dose. This decision was taken in light of the rare clotting events reported with the AstraZeneca vaccine.

Germany also followed suit by recommending the same AstraZeneca/Pfizer combo. The country reportedly allowed this heterologous approach on efficacy grounds.

In July 2021, Thailand became one of the first in Southeast Asia to officially start mixing vaccines. The country’s National Communicable Disease Committee issued a recommendation to give AstraZeneca jabs as the second dose to individuals who had initially received China’s Sinovac (based on inactivated virus technology), to build stronger immunity against the highly contagious delta variant which has created havoc in the country.

South Korea also introduced mix-and-match inoculations, using the AstraZeneca vaccine for the first dose and Pfizer for the second.

WEITERE GESCHICHTEN VON BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries

Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Biotium launches GlycoLiner Cell Surface Glycoprotein Labeling Kits

US-based Biotium, a leading innovator in fluorescent dyes and life science reagents, has announced the launch of GlycoLiner Cell Surface Glycoprotein Labeling Kits for rapid, selective, and covalent labeling of cell surface glycoproteins.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO

Australia-based Vaxxas has announced the appointment of global biopharmaceutical executive David Peacock as Chief Executive Officer (CEO) to lead the commercialisation of the company's proprietary high-density microarray patch (HD-MAP) vaccination technology.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Thermo Fisher partners with NVIDIA leveraging AI to advance scientific instrumentation

US-based Thermo Fisher Scientific Inc. has announced a strategic collaboration with NVIDIA to power artificial intelligence (AI)based solutions and laboratory automation at scale.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Bruker consolidates ownership of TOFWERK in expansion of mass spectrometry portfolio

Bruker Corporation has announced the acquisition of an additional 60 per cent ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker's ownership to 100 per cent.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Bioengineered tissue by Japan emerges as revolutionary treatment for secondary lymphedema

A research team led by Associate Professor Kosuke Kusamori from the Faculty of Pharmaceutical Sciences at Tokyo University of Science (TUS), Japan, is pioneering an innovative technique for lymphatic tissue engineering that could revolutionize the treatment of secondary lymphedema.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Chitose and Fujifilm Biosciences to drive global innovation and biopharma manufacturing

Japan-based Chitose Laboratory Corp. & Fujifilm Biosciences Inc. have announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Vibrant Therapeutics on-boards Dr Han Lee as Co-CEO

Vibrant Therapeutics, a clinical-stage biotechnology company based in China and US, has announced the appointment of Dr Han Lee as co-chief executive officer (CEO).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

IIT-D and AIIMS develop swallowable microdevice for microbiome study

Researchers at the Indian Institute of Technology (IIT) Delhi, and All India Institute of Medical Sciences (AIIMS) have developed an ingestible device that can sample bacteria directly from the small intestine, opening a new window into the human gut microbiome.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Ambitious research to develop multivalent vaccines against multiple deadly filoviruses

Scientists at the University of Oxford, in collaboration with partners, will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus.

time to read

1 min

BioSpectrum Asia Feb 2026

Translate

Share

-
+

Change font size